U.S. Microfluidics Market Size & Outlook, 2023-2030

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to microfluidics market will help companies and investors design strategic landscapes.

Medical was the largest segment with a revenue share of 83.98% in 2023. Horizon Databook has segmented the U.S. microfluidics market based on medical, non-medical covering the revenue growth of each sub-segment from 2018 to 2030.

The demand for microfluidics devices is high in the U.S. owing to increasing research undertaken, government funding, and favorable policies. For instance, MEI Lab announced that it was developing organ-on-a-chip digital twin platforms, as well as 3D implantable and transformable electrodes. The scope of this multiyear project includes assembling 3D structures, optimizing & screening functional materials, and assessing their biocompatibility. Moreover, the FDA’s Center for Devices and Radiological Health (CDRH) is also seeking to advance innovation in medical devices based on microfluidics by developing a regulatory science tool for leakage testing. 

Furthermore, microfluidics entails high levels of skill, and therefore, simplifying through machine learning and AI can encourage its broader use in life sciences and healthcare. For instance, Deepcell, with its AI-based single-cell sorting and analysis technology, is among the first companies to bring the combination of machine learning, AI, and microfluidics into the commercial domain. The technology permitted the delivery of viable and intact single cells with high accuracy and sustained cell viability for downstream characterization. This technology can be used to isolate any type of cell, even those striking at frequencies of less than one in a billion. 

The Translational Genomics Research Institute partnered with the company to employ its new AI-powered sorting and imaging technology to isolate and classify individual diseased cells. In addition to well-established players, the country also harbors various emerging companies that are engaged in manufacturing microfluidics products. For instance, Microfluidics is a U.S.-based company that offers proprietary microfluidics technology, namely Microfluidizer. This technology is incorporated for manufacturing high-shear fluid processors designed to achieve efficient cell disruption, nano emulsions, and reduction of particle size.